Friday 22 November
Auditorium 2
08:30 - 09:30
Plenary Lectures- Session 4
Chairmen
Dr Fernando Bezares
(Argentina)
[cv]
Dr Carlos Chiattone
(Brazil)
[cv]
Dr
Fernando Bezares
Argentina
Curriculum Vitae:
Former Head of Hematology at the Hospital General de Agudos CABA "Teodoro Álvarez" until 2022 and former head of the Division Hematology at Policlínico Bancario (1996-2013).
Active member of GATLA from 1974 to 2023. Coordinator for Argentina of GRELIC (2009-2011). Member of CLL LAG and chairman of the IBAM 2018 held in Buenos Aires.
Has published more than 75 papers in national and international journals and is co-author of more than 150 papers presented at national and international conferences.
He participated in the publication of 6 books related to CLL, Chronic Lymphoproliferative Disorders, and Chronic T Cell Leukemias. He has been co-authoring of the Diagnostic and Treatment Guidelines of the Argentine Society of Hematology since 2009.
Dr
Carlos Chiattone
Brazil
Curriculum Vitae:
He is a bachelor’s degree in medicine from Santa Casa Medical School of São Paulo (FCMSCSP) (1974), a master’s degree in Hematology and Hemotherapy from the Federal University of de Sao Paulo (UNIFESP) (1988), and a Ph.D. from in Internal Medicine at FCMSCSP (2001). Since 2014, he has been a Professor of Medicine (Full Professor) of Internal Medicine and Hematology and Oncology Discipline at FCMSCSP. He was the President of the Brazilian Society of Hematology and Hemotherapy (SBHH) from 2004 to 2009. He was the first president of the Brazilian Association of Hematology, Hemotherapy, and Cellular Therapy (ABHH), an entity resulting from the merging of two previous entities (the Brazilian Society of Hematology and Hemotherapy and the Brazilian College of Hematology). He is the current ABHH Director of International Relations. He is a member of several medical societies, such as ABHH, AIBE, the Brazilian Bone Marrow Transplant Association, ASH, and EHA. He was a member of the Technic Committee of Hematology at the Federal Conseil of Medicine (CFM) from 2011 to 2019. He belongs to the Scientific Counsel of the Brazilian National Cancer Institute (INCA). He is a member of the International Committee of the International Workshop of CLL (IWCLL). He is currently the President of the Italian-Brazilian Society of Hematology (AIBE). He was the president of two previous LAG-CLL meetings held in Brazil. He is one of the organizers of the 5th Latin America Group of CLL (LAG-CLL), which joined with IWCLL (Oct/2024). He has experience in Medicine, acting mainly on the following issues: lymphomas, CLL, PTCL, lymphoma epidemiology, virus and lymphomas, and treatment of lymphoproliferative diseases in low-income countries. He has 172 published articles (Peer-reviewed journals) and 28 book chapters. He was the former editor-chief of the Brazilian Journal of Hematology, Hemotherapy, and Cellular Therapy and is currently the Associated Editor. He is also an ad hoc revisor of Blood Journal.
Speaker:
Dr
Othman Al Sawaf
(Germany)
[cv]
Dr
Othman Al Sawaf
Germany
Curriculum Vitae:
Hematologist & Oncologist. Academic researcher from University of Cologne. Member of the German CLL study group. Principal investigator of phase I l and I l l trials. Key contributor to the CLLI 4 study
Speaker:
Dr
Thomas Kipps
(USA )
[cv]
Curriculum Vitae:
Is Distinguished Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, Director of the Center for Novel Therapeutics, and Co-Director of the Hematologic Malignancies Program at the University of California, San Diego, Moores Cancer Center. Dr. Kipps is a two-time awardee of a Specialized Center of Research (SCOR) in Leukemia grant from the Leukemia and Lymphoma Society, a two-time awardee of the NIH MERIT Award, and principal investigator of the CLL Research Consortium (CRC), which directed inter-institutional research among the leading investigators in CLL from across the country and abroad.
Dr. Kipps is the chair of the international workshop on CLL (iwCLL), and an awardee of the Rai/Binet medal for outstanding contributions to the field of leukemia research